Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate – BioSpace

Sanofi and GSK initiateglobal Phase 3clinical efficacy study of COVID-19 vaccinecandidate

• Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circulating variants
• A booster study program will begin in the coming weeks to complement Phase 3 trial
• Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021

PARIS and LONDON May 27, 2021 Today, Sanofi and GSK started enrollment…

Click here to view the original article.